LogicBio Therapeutics Inc (LOGC)

NASDAQ
2.070
0.000(0.00%)
  • वॉल्यूम:
    0
  • दिन की रेंज:
    2.060 - 2.070
  • 52 सप्ताह रेंज:
    0.257 - 3.440

LOGC समीक्षा

पिछला बंद
2.07
दिन की रेंज
2.06-2.07
आय
10.76M
खुला
2.06
52 सप्ताह रेंज
0.257-3.44
ईपीएस
-0.805
वॉल्यूम
0
मार्केट कैप
68.23M
लाभांश (यील्ड)
N/A
(N/A)
औसत वॉल्यूम (3एम)
523,714
पी/ई अनुपात
-2.57
बीटा
4.62
1- वर्ष बदलाव
-32.24%
बकाया शेयर
32,962,733
अगली कमाई तिथि
02 अप्रैल 2023
LogicBio Therapeutics पर आपकी भावना क्या है?
या
समुदाय परिणामों को देखने के लिए वोट करें!

LogicBio Therapeutics Inc समाचार

  • LogicBio Therapeutics कमाई रिजल्ट, आय पिछाडा Q3 में
    • द्वाराInvesting.com-

    Investing.com - LogicBio Therapeutics ने सोमवार को तीसरी तिमाही के नतीजों में विश्लेषकों के अनुमानों को पिछाडा और आय ने सर्वोच्च करा. कंपनी ने आय प्रति स्टॉक $-0.180 बताया कुल...

LogicBio Therapeutics Inc कंपनी प्रोफाइल

LogicBio Therapeutics Inc कंपनी प्रोफाइल

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company’s GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..

और पढ़ें

तकनीकी सारांश

प्रकार
5 मिनट
15 मिनट
प्रति घंटा
दैनिक
मासिक
मूविंग एवरेजमजबूत खरीदमजबूत खरीदमजबूत खरीदमजबूत खरीदबेचना
तकनीकी संकेतकखरीदेंखरीदेंमजबूत खरीदमजबूत खरीदबेचना
सारांशमजबूत खरीदमजबूत खरीदमजबूत खरीदमजबूत खरीदबेचना